Table 2.
Capsid inhibitors and core protein allosteric modifiers currently undergoing trials
Drug/compound | Clinical study |
---|---|
Morphothiadin (GLS4) | Phase II |
AL-3778 (formerly NVR 3-778) | Phase II |
RO6864018 | Phase II |
AIC 649 | Phase I |
JNJ56136379 | Phase I |
HBV CpAM | Preclinical |
AB-423 | Preclinical |
CpAM core protein allosteric modifier, HBV hepatitis B virus